Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMI 137

Next Previous
Drug Profile

EMI 137

Alternative Names: EMI-137; GE 137

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer Edinburgh Molecular Imaging; GE Healthcare; Kings College London; Netherlands Cancer Institute; University Medical Center Groningen
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Penile cancer; Tongue cancer
  • Phase I/II Breast cancer; Orofacial cancer
  • No development reported Barrett's oesophagus; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Thyroid cancer

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for phase-I development in Thyroid-cancer(Diagnosis) in Netherlands (IV)
  • 12 Dec 2023 EMI 137 is still in phase I development in Thyroid-cancer (Diagnosis) in Netherlands (IV)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Head-and-neck-cancer in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top